Showing results (371-380 of 428) with videos related to

Sort By:
Pageof 43
JAMA Oncology|November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort StudyCaroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Cancers|July 12, 2020
Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in EuropeDavid J Pinato, Alvin J X Lee, Federica Biello, et al.
The Lancet. Oncology|November 11, 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective studyQinghe Zeng, Christophe Klein, Stefano Caruso, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practiceDavid J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal CancerSomaieh Hedayat, Luciano Cascione, David Cunningham, et al.
European Journal of Cancer (Oxford, England : 1990)|November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic indexSebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Journal of Translational Medicine|June 25, 2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohortDaniele Santini, Tea Zeppola, Marco Russano, et al.
Clinical Genitourinary Cancer|May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology SubtypesDimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 27, 2024
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)Zhi-Cheng Jin, Jia-Wei Zhou, Jian-Jian Chen, et al.
Pageof 43